Medical Abortion Clinical Trial
Official title:
Comparison of the Safety, Efficacy, and Feasibility of Medical Abortion Provided by Physicians and Non-physicians in Nepal: a Randomized Controlled, Equivalence Trial.
Verified date | August 2010 |
Source | World Health Organization |
Contact | n/a |
Is FDA regulated | No |
Health authority | Nepal: Ministry of Health and Population |
Study type | Interventional |
The purpose of the study is to compare the safety, effectiveness, and acceptability of medical abortion provided by doctors and midlevel providers in a developing country where doctors are scarce, such as Nepal. This study is the first to evaluate the independent provision of medical abortion by trained nurses and auxiliary nurse midwives compared to doctors by assessing differences in safety, clinical outcomes, case management decision-making, and acceptability. This study provides scientifically valid data on the administration of medical abortion by midlevel providers working independently in a low-resource, developing country setting. The evidence generated by the study will assist policy makers in developing countries interested in expanding safe abortion services by eliminating the legal requirement limiting prescription of medical abortion to doctors where medical abortion is not restricted by law.
Status | Completed |
Enrollment | 1104 |
Est. completion date | July 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 16 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Before randomization: Gestational age not more than 63 days as estimated by last menstrual period (LMP). - After randomization: Gestational age not more than 63 days as estimated by abdominal and bimanual pelvic examination. - Above national age of consent - Willing to return to the clinic for misoprostol on Day 3 and for a follow-up visit on Day 10 to 14. - Residence within the geographical area specified for each clinic and no more than one hour from emergency referral services. - Willing to provide written informed consent to participate in the study and to be randomly assigned to a provider team. - Able to understand the nature of the study, advice and instructions given by health providers. Exclusion Criteria: - Previous allergic reaction to one of the drugs in the medical abortion regimen - Known or suspected ectopic pregnancy or undiagnosed adnexal mass - Inherited porphyria (rare genetic blood diseases) - Chronic adrenal failure - Long term corticosteroid therapy - Haemorrhagic disorder or anticoagulant therapy (blood thinner medications) - IUD in utero that can not be removed before taking mifepristone - Previous enrolment in the study (i.e. no repeat abortions; only one abortion per woman in the study) - Unwilling or unable to return to clinic for follow-up visit. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
Nepal | Center for Research and Environmental Health and Population Activities (CREHPA) | Kathmandu |
Lead Sponsor | Collaborator |
---|---|
World Health Organization | Center for Research and Environmental Health and Population Activities (CREHPA) |
Nepal,
Warriner IK, Meirik O, Hoffman M, Morroni C, Harries J, My Huong NT, Vy ND, Seuc AH. Rates of complication in first-trimester manual vacuum aspiration abortion done by doctors and mid-level providers in South Africa and Vietnam: a randomised controlled equivalence trial. Lancet. 2006 Dec 2;368(9551):1965-72. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete abortion | The primary outcome measure was a successful (complete) abortion, defined as no ongoing pregnancy at clinical examination and no surgical intervention necessary. | 30 days | No |
Secondary | Complications from medical abortion | Defined as life-threatening events requiring hospitalization: haemorrhage requiring a blood transfusion, hospitalization (iv fluids, iv antibiotics), or laparatomy for ectopic pregnancies. | 30 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02745093 -
Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks
|
Phase 4 | |
Completed |
NCT02570204 -
Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests
|
N/A | |
Completed |
NCT01487213 -
Routine Follow-up Versus Self-assessment in Medical Abortion
|
N/A | |
Terminated |
NCT05119439 -
Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks
|
Phase 4 | |
Terminated |
NCT04941443 -
Methadone and Medication Abortion
|
Phase 4 | |
Completed |
NCT02985229 -
Acceptability and Feasibility of Medical Abortion in Singapore
|
Phase 3 | |
Completed |
NCT01920022 -
Quickstart of Nexplanon® at Medical Abortion
|
Phase 4 | |
Completed |
NCT00472394 -
Determining Women's Preferences for Medical Abortion Using Willingness to Pay
|
N/A | |
Completed |
NCT03604341 -
Cannabinoids for Pain Control During Medical Abortion
|
Phase 4 | |
Completed |
NCT00907725 -
Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?
|
N/A | |
Completed |
NCT00120224 -
De-Medicalizing Mifepristone Medical Abortion
|
N/A | |
Completed |
NCT03148587 -
Medical Abortion Self-Confirmation (MASC)
|
N/A | |
Completed |
NCT00621543 -
Insertion of an Intrauterine Device (IUD) After Medical Abortion
|
N/A | |
Completed |
NCT02343913 -
Simplifying Menstrual Regulation (MR): Post Abortion Care in Pakistan
|
N/A | |
Completed |
NCT01856777 -
Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy
|
N/A | |
Recruiting |
NCT00920465 -
Treatment Regimens for Mifegyne and Cytotec
|
Phase 3 | |
Completed |
NCT05532085 -
Assessment of Pain During an Abortion With Knowledge of the Predictive Factors of Pain.
|
||
Completed |
NCT00997347 -
The Extended Gestational Age Medical Abortion Study
|
Phase 4 | |
Completed |
NCT03014193 -
Simplifying First Trimester Medical Abortion Follow-up
|
N/A | |
Recruiting |
NCT04905251 -
Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
|